
Arena Blog
Data-driven insights on trading strategies, backtests, and market analysis.
We Just Shipped an API That Charges $0.01 Per Call — In USDC, On-Chain, No Account
Phase 4 is live: the same Bitcoin cycle data, on-chain indicators, and aggregated strategy insights now reachable through three channels — REST, MCP, and x402 pay-per-call in USDC on Base. No account required for the third. An AI agent gets HTTP 402, signs a USDC authorization, retries, and has the data three seconds later. What's actually live, why we built it this way, and the Coinbase detour that cost us a day.
We're Opening Our API: REST + MCP + (soon) x402
For 18 months we've been quietly building Backtesting Arena — a platform where 500+ users have run 10,000+ backtests across Bitcoin, stocks, ETFs, commodities, and forex. Daily cycle scores, on-chain indicators, sentiment dashboards, strategy insights. All powered by the same data layer that's been running on a private quasi-API.
AI Agents and Crypto Payments: Where This Is Really Heading
This is the crypto-rail deep-dive companion to our earlier piece [AI and the Future of Payment Systems](https://tradingstrategies.work/blog/ai-future-of-payment-systems-2026), which covered the broader fintech picture including Visa Intelligent Commerce and Mastercard Agent Pay. Here we zoom in on what's happening on the crypto layer specifically.
Is Crypto Safe? Why Crypto Looks Less Secure Than It Is
The "hacked again" reflex is wrong. What the Polymarket case actually shows — and the two places where crypto genuinely is harder.
40,000 Backtests — What the Data Says Now (and What Changed Since 10k)
Five weeks ago it was 10,000 backtests; today it's over 40,000. With 4x the data, the "beats Buy & Hold" rate falls from 64% to 52%, four in five runs land below 50% win rate, and one memecoin still holds its 197,923% record. What selection bias does to sample size — on real numbers.
Option vs. Annuity Machine: Two Ways to Be Invested in the Same AI-Healthcare Sector
"Invested in AI healthcare" can mean two almost opposite things. Two real companies show it: an annuity machine with ~86% recurring revenue — and an option with not a single approved drug. Same label, opposite risk DNA.
Why SMC Indicators Look Better Than They Backtest
A smart-money indicator paints clean zones that price seems to respect. Backtest it honestly and the magic fades. The reason is mechanical — repainting and vanished losers — not your skill.
Why the same strategy crushes crypto and bombs the S&P 500
We ran the same RSI/SMA crossover across the top 50 coins and the top 50 US stocks — identical rules, identical window. On crypto it beats the buy-and-hold benchmark 80 % of the time; on stocks, 4 %. Why a trend-following strategy works in one market and bleeds in the other.
The Gap-Fill Myth: Do Price Gaps Really Fill — and the End of the CME Gap
"Price gaps always fill" is a myth. What the evidence actually shows — for stock gaps, and for the CME gap, which became history in May 2026.
STRC & MSTR Explained: Mechanics, Myths, Risks and Opportunities
STRC is below par and the debate is loud. We separate mechanics from myth: how STRC and MSTR work, the misconceptions circulating, and where the risk and the opportunity sit.
Don't miss new blog posts
One short email per new post — strategies, backtests, market analysis. No spam, unsubscribe with one click anytime.
By subscribing you accept our privacy policy. We use Resend for delivery. Double opt-in confirmation required.